Time-Restricted Eating to Improve Cardiometabolic Health (NY-TREAT Study)

Dr. Blandine Laferrère

The New York-TREAT study is a lifestyle intervention administered via a smartphone application that aims to improve cardiometabolic health (blood pressure, blood glucose, cholesterol levels, etc.) in adults aged 50 to 75 years, with overweight or obesity, diet-treated or metformin-treated type 2 diabetes, or prediabetes. The NY-TREAT study will test whether self-monitoring food intake with a smartphone and decreasing the number of hours people eat each day affects body fat, sleep, and blood sugar.

Click here for more details

Time-Restricted Eating to Improve Cardiometabolic Health (NY-TREAT Study)

The New York-TREAT study is a randomized trial that will examine the effect of self-monitoring food intake via a smart phone application, and of a novel lifestyle intervention called time restricted eating, on improvement of metabolic health in persons with overweight or obesity and with prediabetes or type 2 diabetes. The intervention lasts 12 months and will be administered via a smartphone app. Participants will use the app to take pictures of all food and drinks, every day for 3 months, then 10 days a month for the following 9 months. Participation requires one screening visit (~1hr), and seven outpatient visits (~1-5hr) including an IV catheter in your arm for blood samples. In addition to potential health benefits, you will get your body fat and energy expenditure measured and you can receive up to $2000 total compensation.

We are recruiting 50-75 year old adults with overweight or obesity, type 2 Diabetes or Prediabetes.

You may be eligible if you have:

  • BMI between 25 and 46 kg/m2
  • A smartphone
  • Can read and speak English

You may not be eligible if you:

  • Are engaging in a current weight loss program or diet
  • Take medication for weight loss or for diabetes, with the exception of metformin
  • Have a history of heart failure/kidney failure/liver failure/ and/or lung disease
  • Work night shifts

See if you may be eligible:

https://cumc.co1.qualtrics.com/jfe/form/SV_5ztwcztAVs4CT9Y

This is a randomized trial which means you will either:

  • Continue to eat and drink in your habitual hours OR
  • Reduce the number of hours you eat to a set window of time

Study involves:

  • Participation over the course of 12 months

Sleep stability, weight, and glycemic control 

Dr. Blandine Laferrère, MD, PhD and Dr. Marie Pierre StOnge, Co- Principal Investigators

The main goal of this study is to test whether reducing variability in rest/activity and sleep improves glycemic control and body composition in adults with pre-diabetes. Variability in lifestyle behaviors has been associated with adverse health, specifically poor glucose control. The overall goal of this project is to assess the role of rest-activity patterns on glucose control, body composition, and well-being. We are currently looking for non-smoking men and women, age 25 years or older and with pre-diabetes (HbA1c 5.7-6.4%) to participate in this study.  

Click here for more details

The Lifestyle Patterns Study

We seek to enroll participants with pre-diabetes who have erratic lifestyle behaviors. Participants are randomized to either maintain their usual habits (control group) or more routine stable behaviors (stability group). The screening process will take approximately 2 weeks and the study will last an additional 16 weeks. Testing will occur at the onset of the study and after 12 weeks. A follow-up visit at week 16 will also be scheduled. Before the start of the 12-week period, all participants track their sleep for 2 weeks and wear a glucose monitor to measure their glucose levels. At the start and end of the 12-week period, participants come to the research lab to undergo a glucose tolerance test. This test measures how their body reacts to a glucose load. They also undergo magnetic resonance imaging and spectroscopy scanning. This scan will provide information on body composition and liver fat content. Compensation up to $500 will be provided.

We are recruiting adults 25 years old or older with pre-diabetes.

You may be eligible if you have:

  • BMI between 25 and 39.9 kg/m2
  • A variable schedule

You may not be eligible if you:

  • Take medication for weight loss or pre-diabetes, with the exception of metformin
  • Have history of heart failure/ kidney failure/ liver failure/ and/or lung disease
  • Take medication for a psychiatric/psychological disorder

See if you may be eligible:

RecruitMe (columbia.edu)

This is a randomized trial which means you will either:

  • Continue to follow your habitual schedule and lifestyle patterns
  • Be asked to make slight changes to your schedule and lifestyle patterns

Study involves:

  • Participation over 3-4 months
  • Measurement of body composition and blood glucose levels
  • 12 visits to Columbia University Research Center
  • You may receive up to $500 for your participation in the study

For more information:

If you are interested to hear more and find out whether you qualify, please contact the study coordinator Lara Bond via email at lsb2173@cumc.columbia.edu or call (917) 581-4637.

Alzheimer's Disease and Alzheimer's Disease Related Dementias in Prediabetes and Type 2 Diabetes: The Diabetes Prevention Program Outcomes Study AD/ADRD Project 

Dr. Blandine Laferrère, MD, PhD, Principal Investigator of the Columbia University study site

The NIDDK-sponsored Diabetes Prevention Program (DPP) and ongoing DPP Outcomes Study (DPPOS) are major studies that changed the way people approach type 2 diabetes prevention worldwide. The DPP showed that people who are at high risk for type 2 diabetes can prevent or delay the disease by losing a modest amount of weight through lifestyle changes (dietary changes and increased physical activity). Taking metformin, a safe and effective generic medicine to treat diabetes, was also found to prevent the disease, though to a lesser degree. 

The DPPOS has continued to follow most DPP participants since 2002. To date, the DPPOS has shown that participants who took part in the DPP Lifestyle Change Program or are taking metformin continue to prevent or delay type 2 diabetes for at least 15 years. The DPPOS has also shown that the DPP Lifestyle Change Program is cost effective (costs are justified by the benefits of diabetes prevention, improved health, and fewer health care costs) and metformin is cost-saving (leads to a small savings in health care costs) after 10-years. DPPOS researchers are also continuing to follow other health problems in participants such as cancer, cardiovascular diseases (heart and blood vessel disease), nerve damage, kidney disease, and eye disease. As participants age, researchers are following age-related health problems such as trouble with physical function and difficulties with thinking or memory. 

The main goal of the continuation of DPPOS, the NIA funded DPP-AD-ADRD U19 multicenter project, is to address one of the most important, complex questions in Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD) research: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes and type 2 diabetes, who are a high-risk group for cognitive impairment and represent a large fraction of the United States population? 

Click here for more information about the DPP